United Therapeutics Corporation (UTHR) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High Margins • Strong Liquidity • Premium Valuation UTHR is a highly profitable, cash-rich, low-risk business with strong growth and margins, but its premium valuation and modest asset efficiency limit upside.
Price Behavior
Key Price Behavior Insights: • Uptrend intact • Cooling momentum • Range compression Support Level: $560-$565 Resistance Level: $588-$593 UTHR's longer-term trend remains up over the last month, but short-term momentum has cooled after a sharp late-March spike, with $560-$565 acting as key support and $588-$593 as the main resistance to reclaim.
Sentiment & News
Key News Insights: • Phase 3 Momentum • Earnings Beat Watch • Insider Sales United Therapeutics is drawing bullish attention from strong Phase 3 Tyvaso data, potential earnings upside, and heavy trading activity, though insider sales and longer-term risks remain in focus.
AI Summary
UTHR is transitioning from a high-quality cash-generating specialty biotech into a potential lung-disease platform re-rating story, with Tyvaso's late-stage IPF data as the key upside catalyst, but the stock already prices in meaningful success so near-term returns now hinge on clinical/regulatory execution rather than balance-sheet strength alone.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |